CD39 has an essential role in converting extracellular adenosine triphosphate (ATP; pro-inflammatory) into adenosine monophosphate (AMP; anti-inflammatory). Preventing the action of CD39 in the tumor microenvironment would increase levels of ATP, causing myeloid cell activation and improvement of tumor control.

New and updated preclinical data presented at the Society for Immunotherapy of Cancer's Annual Meeting in Boston, by: Actym, Calidi, Cantargia, Cytovia, Enara Bio, Immunome, Leap, Lyell Immunopharma, TCR2.